News

Intersect Diagnostics Inc., a translational biomarker laboratory developing quantitative, multi-omic spatial discovery assays using state-of-the-art technologies, is pleased to announce the appointment of cancer biomarker scientist Mohan Singh, PhD to the company's Scientific Advisory Board.

Intersect Diagnostics Inc., a translational biomarker laboratory developing quantitative, multi-omic spatial discovery assays using state-of-the-art technologies, is pleased to announce the appointment of Kyle Fox, MBA as the company's Head of Corporate Development.

Intersect Diagnostics Inc. is pleased to be presenting our company this Wednesday, May 26 at 1:15 pm PST at LA BEST 2021 - the annual Bioscience Ecosystem Summit hosted by UCLA Technology Development Group! We are looking forward to a great conference and hope to see you all there!

Intersect Diagnostics Inc. is pleased to announce the appointment of renowned data scientist Paul Boutros, PhD, MBA to the company's Scientific Advisory Board. Dr. Boutros is director of the UCLA Jonsson Comprehensive Cancer Center’s Cancer Data Science program and associate director of cancer informatics at the UCLA Institute for [...]

Intersect Diagnostics Inc. is pleased to announce today the filing of a provisional patent application with the United States Patent & Trademark Office (USPTO) directed to the company's assay development methodologies in the emerging high-parameter spatial discovery space. The application, titled "Method For Developing A Highly Multiplexed Immuno-Oncology Assay," [...]

Intersect Diagnostics congratulates Intersect CFO, Ed Sitar, for his well-deserved appointment as a member of the Board of Directors and Chair of the Audit Committee at Timber Pharmaceuticals (NYSE: TMBR)! Read More About Ed Sitar's Appointment